Restrepo A, Gómez I, Cano L E, Arango M D, Gutiérrez F, Sanín A, Robledo M A
Am J Med. 1983 Jan 24;74(1B):48-52. doi: 10.1016/0002-9343(83)90513-2.
The results of ketoconazole therapy in 38 patients with active paracoccidioidomycosis are described. Treatment consisted of a 200 mg tablet a day for 6 months. Evaluation was accomplished by means of a scoring system and the results were as follows: none of the patients worsened during therapy, one was found to be unchanged, five had minor improvement, 330 had major improvement, and there was complete resolution of the pretherapy conditions in 13. These findings plus the lack of toxicity of the drug and the facility for oral administration, make of ketoconazole a first line drug for the treatment of paracoccidioidomycosis.
本文描述了38例活动性副球孢子菌病患者接受酮康唑治疗的结果。治疗方法为每日服用一片200毫克的片剂,持续6个月。通过评分系统进行评估,结果如下:治疗期间无患者病情恶化,1例病情无变化,5例有轻微改善,30例有显著改善,13例患者治疗前的症状完全消失。这些结果加上该药物无毒性且便于口服,使得酮康唑成为治疗副球孢子菌病的一线药物。 (注:原文中“330 had major improvement”疑似有误,应为“30 had major improvement”,译文按修正后翻译)